同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300636 同和药业

已收盘 11-22 15:00:00

{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":8.32,"timestamp":1732258998000,"preClose":8.73,"halted":0,"volume":9376850,"delay":0,"floatShares":364000000,"shares":422000000,"eps":0.292,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.41,"latestTime":"11-22 15:00:00","open":8.78,"high":8.79,"low":8.3,"amount":79739900,"amplitude":0.0561,"askPrice":8.33,"askSize":178,"bidPrice":8.32,"bidSize":44,"shortable":0,"etf":0,"ttmEps":0.292,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":8.73,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":9.6,"lowLimit":7.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":421527350,"pbRate":1.59,"roa":"--","roe":"4.22%","epsLYR":0.2786,"committee":0.280065,"marketValue":3507000000,"floatMarketCap":3032000000,"peRate":28.493151,"changeRate":-0.047,"turnoverRate":0.0257,"status":1},"requestUrl":"/m/hq/s/300636","defaultTab":"news","newsList":[{"id":"2485923949","title":"同和药业最新公告：获得利伐沙班片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2485923949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485923949?lang=zh_cn&edition=full","pubTime":"2024-11-22 17:11","pubTimestamp":1732266694,"startTime":"0","endTime":"0","summary":"同和药业公告，公司近日收到国家药监局核准签发的利伐沙班片的《药品注册证书》。该药品为化学药品4类，规格包括10mg、15mg、20mg。利伐沙班是一种口服的Xa因子抑制剂，临床用于成人及儿童血栓事件的预防和治疗。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200027696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2485236979","title":"同和药业(300636.SZ)：利伐沙班片取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2485236979","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485236979?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:54","pubTimestamp":1732265650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日收到国家药品监督管理局核准签发的利伐沙班片的《药品注册证书》。利伐沙班是一种口服的Xa因子抑制剂，临床用于成人及儿童血栓事件的预防和治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2483208360","title":"同和药业最新公告：公司原料药“美阿沙坦钾”通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2483208360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483208360?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:45","pubTimestamp":1731487550,"startTime":"0","endTime":"0","summary":"同和药业公告，公司提交的“美阿沙坦钾”原料药已通过CDE审批，登记号为Y20220001325，企业名称为江西同和药业股份有限公司，产品来源为境内生产。该原料药适用于治疗成人原发性高血压。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300026741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2483021714","title":"同和药业(300636.SZ)：美阿沙坦钾原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2483021714","media":"智通财经网","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483021714?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:10","pubTimestamp":1731485448,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉，公司提交的“美阿沙坦钾”原料药通过了CDE审批。美阿沙坦钾适用于治疗成人原发性高血压。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4017","BK0239","300636","CDE"],"gpt_icon":0},{"id":"2482672065","title":"同和药业最新公告：公司通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2482672065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482672065?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:01","pubTimestamp":1731402079,"startTime":"0","endTime":"0","summary":"同和药业公告，公司近日收到江西省药品监督管理局的药品GMP符合性检查结果告知书，经现场检查和综合评定，公司本次检查原料药克立硼罗符合药品GMP。克立硼罗适用于2岁及以上轻度至中度特应性皮炎患者的局部外用治疗。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200028393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2482722092","title":"同和药业(300636.SZ)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2482722092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482722092?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:47","pubTimestamp":1731401246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日收到江西省药品监督管理局的“江西省药品监督管理局药品GMP符合性检查结果告知书，获悉经现场检查和综合评定,公司本次检查原料药克立硼罗符合药品GMP。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2478141471","title":"同和药业：东吴医药、中泰证券等多家机构于10月24日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2478141471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478141471?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:42","pubTimestamp":1730079761,"startTime":"0","endTime":"0","summary":"同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。同和药业2024年三季报显示，公司主营收入5.7亿元，同比上升1.84%；归母净利润9573.65万元，同比上升21.72%；扣非净利润9306.13万元，同比上升29.91%；其中2024年第三季度，公司单季度主营收入1.88亿元，同比上升5.61%；单季度归母净利润2618.44万元，同比上升21.1%；单季度扣非净利润2553.5万元，同比上升15.94%；负债率29.91%，投资收益60.67万元，财务费用-1303.16万元，毛利率33.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800003513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK0276","600918","BK1515","BK1574","300636","09939","159938"],"gpt_icon":0},{"id":"2478113573","title":"【机构调研记录】红塔红土调研洁特生物、同和药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2478113573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478113573?lang=zh_cn&edition=full","pubTime":"2024-10-28 08:02","pubTimestamp":1730073759,"startTime":"0","endTime":"0","summary":"红塔红土成立于2012年，截至目前，资产管理规模34.74亿元，排名165/207；资产管理规模24.22亿元，排名153/207；管理公募基金数40只，排名112/207；旗下公募基金经理5人，排名141/207。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为1.22，近一年增长30.87%。旗下最新募集公募基金产品为红塔红土30天持有期债券A，类型为债券型-长债，集中认购期2024年10月28日至2024年11月8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239","BK0220","688026"],"gpt_icon":0},{"id":"2478135621","title":"【机构调研记录】湘财基金调研上海钢联、同和药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2478135621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478135621?lang=zh_cn&edition=full","pubTime":"2024-10-28 08:02","pubTimestamp":1730073755,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月25日披露的机构调研信息，湘财基金近期对2家上市公司进行了调研，相关名单如下：1）上海钢联 个股亮点：公司旗下“我的钢铁”APP鸿蒙版已正式登陆华为鸿蒙系统应用商店，成为首批受邀接入鸿蒙系统的应用之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800001175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0137","BK0217","BK0188","BK0055","300636","300226","BK0239","BK0095"],"gpt_icon":0},{"id":"2478113578","title":"【机构调研记录】惠升基金调研优利德、同和药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2478113578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478113578?lang=zh_cn&edition=full","pubTime":"2024-10-28 08:02","pubTimestamp":1730073735,"startTime":"0","endTime":"0","summary":"惠升基金成立于2018年，截至目前，资产管理规模495.71亿元，排名84/207；资产管理规模495.7亿元，排名73/207；管理公募基金数41只，排名109/207；旗下公募基金经理10人，排名109/207。旗下最近一年表现最佳的公募基金产品为惠升领先优选混合A，最新单位净值为1.24，近一年增长44.16%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800001140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688628","BK0239","300636","BK0225"],"gpt_icon":0},{"id":"2478613805","title":"平安证券：给予同和药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478613805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478613805?lang=zh_cn&edition=full","pubTime":"2024-10-27 13:05","pubTimestamp":1730005528,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟,臧文清近期对同和药业进行研究并发布了研究报告《利润端维持较快增长，新品种高端市场放量有望加速》，本报告对同和药业给出增持评级，当前股价为8.85元。同和药业重点聚焦美国为代表的高端市场，2024年公司新产品高端市场在手订单同比增加1.1-1.3亿元，其中新品销量将占据主导地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700012095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","161027"],"gpt_icon":0},{"id":"2478973176","title":"同和药业（300636）2024年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478973176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478973176?lang=zh_cn&edition=full","pubTime":"2024-10-25 06:08","pubTimestamp":1729807721,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期同和药业发布2024年三季报。截至本报告期末，公司营业总收入5.7亿元，同比上升1.84%，归母净利润9573.65万元，同比上升21.72%。按单季度数据看，第三季度营业总收入1.88亿元，同比上升5.61%，第三季度归母净利润2618.44万元，同比上升21.1%。本报告期同和药业应收账款上升，应收账款同比增幅达39.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500005302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636"],"gpt_icon":0},{"id":"2477509530","title":"太平洋：给予同和药业买入评级，目标价位10.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477509530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477509530?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:21","pubTimestamp":1729761701,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对同和药业进行研究并发布了研究报告《Q3营收稳定增长，利润略低于市场预期》，本报告对同和药业给出买入评级，认为其目标价位为10.50元，当前股价为8.5元，预期上涨幅度为23.53%。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为12.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400030365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","601099"],"gpt_icon":0},{"id":"2477579009","title":"同和药业（300636）10月24日主力资金净卖出2727.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477579009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477579009?lang=zh_cn&edition=full","pubTime":"2024-10-24 15:28","pubTimestamp":1729754896,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月24日收盘，同和药业报收于8.5元，下跌3.63%，换手率3.7%，成交量13.47万手，成交额1.16亿元。10月24日的资金流向数据方面，主力资金净流出2727.74万元，占总成交额23.49%，游资资金净流入1339.07万元，占总成交额11.53%，散户资金净流入1388.67万元，占总成交额11.96%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为12.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400019600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2477377273","title":"同和药业最新公告：第三季度净利润2618.44万元 同比增长21.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477377273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477377273?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:39","pubTimestamp":1729672769,"startTime":"0","endTime":"0","summary":"同和药业2024年第三季度报告显示，公司前三季度实现营业收入5.69亿元，同比增长1.84%；归属于上市公司股东的净利润9573.65万元，同比增长21.72%。其中，第三季度营收1.88亿元，同比增长5.61%，净利润2618.44万元，同比增长21.10%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300026822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636"],"gpt_icon":0},{"id":"2477737189","title":"同和药业(300636.SZ)发布前三季度业绩，净利润9573.65万元，同比增长21.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477737189","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477737189?lang=zh_cn&edition=full","pubTime":"2024-10-23 15:52","pubTimestamp":1729669966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布2024年三季度报告，前三季度，公司实现营业收入5.7亿元，同比增长1.84%。归属于上市公司股东的净利润9573.65万元，同比增长21.72%。归属于上市公司股东的扣除非经常性损益的净利润9306.13万元，同比增长29.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636"],"gpt_icon":0},{"id":"2477801442","title":"10月22日同和药业涨5.65%，财通资管健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477801442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477801442?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:18","pubTimestamp":1729585132,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日同和药业涨5.65%，收盘报8.98元，换手率3.64%，成交量13.26万手，成交额1.18亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为财通资管健康产业混合A。财通资管健康产业混合A目前规模为3.45亿元，最新净值0.8887，较上一交易日上涨0.91%，近一年下跌2.5%。财通资管健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200024571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2477480121","title":"同和药业涨5.65%，太平洋一个月前给出“买入”评级，目标价11.88元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477480121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477480121?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:18","pubTimestamp":1729585128,"startTime":"0","endTime":"0","summary":"今日同和药业涨5.65%，收盘报8.98元。2024年8月30日，太平洋研究员周豫,乔露阳发布了对同和药业的研报《Q2业绩略低于市场预期，产能投放有望助力新产品法规市场放量》，该研报对同和药业给出“买入”评级，认为其目标价为11.88元，现价距离目标价尚有32.29%的涨幅空间。研报中预测公司2024/25/26年营收为9.00/12.41/15.84亿元，归母净利润为1.80/2.58/3.43亿元，对应当前PE为18/13/10X，持续给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200024569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300636"],"gpt_icon":0},{"id":"2477780332","title":"同和药业（300636）10月22日主力资金净买入714.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477780332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477780332?lang=zh_cn&edition=full","pubTime":"2024-10-22 15:20","pubTimestamp":1729581656,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月22日收盘，同和药业报收于8.98元，上涨5.65%，换手率3.64%，成交量13.26万手，成交额1.18亿元。10月22日的资金流向数据方面，主力资金净流入714.35万元，占总成交额6.08%，游资资金净流出99.15万元，占总成交额0.84%，散户资金净流出615.21万元，占总成交额5.23%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为12.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200018171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2475937841","title":"10月16日同和药业发生1笔大宗交易 成交金额216.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475937841","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475937841?lang=zh_cn&edition=full","pubTime":"2024-10-16 16:43","pubTimestamp":1729068202,"startTime":"0","endTime":"0","summary":"证券之星消息，10月16日同和药业发生大宗交易，交易数据如下：大宗交易成交价格8.43元，相对当日收盘价溢价2.93%，成交25.67万股，成交金额216.4万元，买方营业部为华泰证券股份有限公司重庆江北嘴证券营业部，卖方营业部为国泰君安证券股份有限公司广州东风中路证券营业部。截至2024年10月16日收盘，同和药业报收于8.19元，下跌0.36%，换手率1.37%，成交量5.0万手，成交额4102.7万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101600025684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","stockEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0567},{"period":"3month","weight":0.0426},{"period":"6month","weight":-0.1923},{"period":"1year","weight":-0.2952},{"period":"ytd","weight":-0.2076}],"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","perCapita":"23737股","boardName":"医药制造业","registeredCapital":"42152万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　江西同和药业股份有限公司主营业务为化学原料药和医药中间体的研发、生产和销售，主要产品方向为特色化学原料药及中间体、专利原料药中间体。公司是技术驱动型企业，连续多年研发投入占销售额的比例保持在8%-9%，多次被认定为高新技术企业，先后获批组建了“江西省特色原料药工程技术研究中心”、“国家博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台，具有强大的研发能力和技术创新能力。","serverTime":1732316563597,"listedPrice":14.47,"stockholders":"15352人(较上一季度增加19.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}